[{"orgOrder":0,"company":"USpharma","sponsor":"1315 Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Milnacipran HCl","moa":"Norepinephrine transporter | Serotonin transporter","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"USpharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"USpharma \/ 1315 Capital","highestDevelopmentStatusID":"15","companyTruncated":"USpharma \/ 1315 Capital"}]

Find Clinical Drug Pipeline Developments & Deals by USpharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : The capital infusion will enable USpharma to accelerate the development and commercialization of its pipeline, including Milnacipran tablets reference product of Savella.

                          Product Name : Savella-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 30, 2025

                          Lead Product(s) : Milnacipran HCl

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : 1315 Capital

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank